Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Final results from this study, after median follow-up of 80 months, found no statistically significant difference in median overall survival (secondary endpoint) between gefitinib and vinorelbine plus cisplatin (75.5 vs. 62.8 months, respectively; HR 0.92; 95% CI 0.62-1.36)

Journal of Clinical Oncology